Results 31 to 40 of about 2,223,665 (257)

Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma. [PDF]

Int J Surg
Primary liver cancer is a major global health challenge, of which hepatocellular carcinoma is the most common. For patients with advanced liver cancer, Sorafenib is a first-line targeted drug that occupies a dominant position in clinical applications.
Huang C, Li Y, Zhang F, Zhang C, Ding Z.
europepmc   +3 more sources

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma

Cancer Cell International, 2023
Background Hepatocellular carcinoma (HCC) accounts for almost 80% of all liver cancer cases and is the sixth most common cancer and the second most common cause of cancer-related death worldwide.
Hung-Wen Tsai, Yi-Li Chen, Chun-I Wang, Ching‑Chuan Hsieh, Yang-Hsiang Lin, Pei-Ming Chu, Yuh-Harn Wu, Yi-Ching Huang, Cheng-Yi Chen   +8 more
doaj   +1 more source

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma

iScience, 2023
Summary: Sorafenib induces ferroptosis, making it a useful treatment against advanced liver hepatocellular carcinoma (LIHC). However, sorafenib resistance is extremely common among LIHC patients.
Mengxing Cai, Jingwen Luo, Chunxiu Yang, Xiaopeng Yang, Cheng Zhang, Lixin Ma, Yibin Cheng   +6 more
doaj   +1 more source

YB-1 transcription factor promotes Sorafenib resistance in Liver Cancer [PDF]

, 2023
Background: Hepatocellular carcinoma (HCC) is a primary malignant liver tumor that commonly occurs as a progression of chronic liver inflammation.
Dhevan, Vijian, Sudershan, D., Lopez, S., Leslie, Sophia M., Satapathy, Sanjaya, Chuahan, Subhash C, Karkoutly, Omar, Ezell, Kristopher L., Anilkumar, Adithya, Doxtater, Kyle, Kotnala, Sudhir, Tripathi, Manish   +11 more
core   +1 more source

Autophagy Facilitates the Sorafenib Resistance of Hepatocellular Carcinoma Cells [PDF]

West Indian Medical Journal, 2014
Liver cancer is the second most frequent cause of cancer death in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) represents the major subtype in liver cancer and its five-year survival rate remains very poor.
B, Liu, Y, Cao, H, Jiang, A, Mao
openaire   +2 more sources

Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.

, 2021
Background: We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab.Case report: Case 1: A 50-year-old man with RCC received nivolumab as ...
FUJIMOTO, Noriki, 8611, 50378460, KAGEYAMA, Susumu, KAWAUCHI, Akihiro, 8612, 6456, 2909, KATO, Takeshi, 2792, 2890, 小出, 博義, TERADA, Tomohiro, 0000-0001-7150-647X, 674, 675, 吉田, 哲也, 10324641, 60510310, 河内, 明宏, 寺田, 智祐, KOIDE, Hiroyoshi, 6322, 影山, 進, 50378452, 60865707, 90240952, 野田, 哲史, 藤本, 徳毅, 0000-0003-4051-0649, 0000-0001-9969-7159, NODA, Satoshi, 0000-0001-6344-4440, 寺村, 和也, 加藤, 威, TERAMURA, Kazuya, YOSHIDA, Tetsuya   +36 more
core   +1 more source

A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy

Frontiers in Cell and Developmental Biology, 2023
Patients with hepatocellular carcinoma (HCC) bear a heavy burden of disease and economic burden but have fewer treatment options. Sorafenib, a multi-kinase inhibitor, is the only approved drug that can be used to limit the progression of inoperable or ...
Kangnan Zhang, Qinghui Zhang, Rongrong Jia, Shihao Xiang, Ling Xu   +4 more
doaj   +1 more source

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel [PDF]

, 2013
Introduction: Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK) pathway and VEGFR kinases.
John M Kirkwood, Keith T Flaherty, Fengmin Zhao (139710), Kluger Harriet M., Wilson, M, Harriet M Kluger, Jilaveanu Lucia B., Rimm, DL, Lee, Sandra J., Kurt D'Andrea (442217), Rimm David L., Harriet M. Kluger (184091), Kluger, HM, D'Andrea, Kurt, Zhao, F, Kurt D'Andrea, Melissa Wilson (442218), Keith T. Flaherty (226339), Nathanson, KL, Kirkwood, John M., Sandra J. Lee (213144), Lee Sandra J., Fengmin Zhao, D'Andrea, K, Zhao, Fengmin, David L. Rimm (323315), Kirkwood, JM, Flaherty Keith T., Kirkwood John M., Sandra J Lee, Wilson Melissa, Katherine L Nathanson, Flaherty, Keith T., Jilaveanu, LB, John M. Kirkwood (141762), David L Rimm, Rimm, David L., Nathanson Katherine L., Zito, Christopher R., D'Andrea Kurt, Zito, CR, Lucia B Jilaveanu, Zhao Fengmin, Wilson, Melissa, Jilaveanu, Lucia B., Flaherty, KT, Lee, SJ, Katherine L. Nathanson (154077), Melissa Wilson, Smalley, Keiran, Lucia B. Jilaveanu (184077), Kluger, Harriet M., Christopher R. Zito (184074), Zito Christopher R., Christopher R Zito, Nathanson, Katherine L.   +55 more
core   +2 more sources

PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC [PDF]

Molecular Cancer Research, 2017
Abstract The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. Here, we report metabolic reprogramming in sorafenib-resistant HCC and identify a regulatory molecule, peroxisome proliferator–activated ...
Mi-Jin, Kim, Yeon-Kyung, Choi, Soo Young, Park, Se Young, Jang, Jung Yi, Lee, Hye Jin, Ham, Byung-Gyu, Kim, Hui-Jeon, Jeon, Ji-Hyun, Kim, Jung-Guk, Kim, In-Kyu, Lee, Keun-Gyu, Park   +11 more
openaire   +2 more sources

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma [PDF]

Journal of Biomedical Science, 2022
Abstract Background Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and has a high mortality rate worldwide. Sorafenib is the only systemic treatment demonstrating a statistically significant but modest overall survival benefit.
You-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen   +3 more
openaire   +3 more sources